Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial. (PubMed, Nat Med) - Sep 23, 2026 - P1/2 | "These findings suggest that upfront HER2-targeted therapeutic intensification in BTC may represent a promising direction for future first-line treatment strategies, with relevance to ongoing phase 3 studies. ClinicalTrials.gov identifier: NCT05749900 ."
IO biomarker • Journal • P1/2 data • Biliary Cancer • Biliary Tract Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia • HER-2
|
|
Beodeul Kang; Chang Gon Kim; Chang Ho Ahn; Changhoon Yoo; Choong-Kun Lee; Dong-Hoe Koo; Hong Jae Chon; Hye Jin Choi; Il Hwan Kim; Jin Won Kim; Ju Won Kim; JungHun Kang; Minsuk Kwon; Se Jun Park; Sejung Park; Sora Kang; Taek Chung; Woo Kyun Bae; Woochan Hwang
|